SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 101 filers reported holding SPERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -95.5% | 1,934 | -25.1% | 0.00% | – |
| Q1 2022 | $22,000 | -45.0% | 2,581 | +4.6% | 0.00% | – |
| Q4 2021 | $40,000 | -11.1% | 2,467 | 0.0% | 0.00% | – |
| Q3 2021 | $45,000 | +25.0% | 2,467 | -3.6% | 0.00% | – |
| Q2 2021 | $36,000 | +12.5% | 2,559 | +18.0% | 0.00% | – |
| Q1 2021 | $32,000 | -84.2% | 2,169 | -79.1% | 0.00% | – |
| Q4 2020 | $202,000 | +83.6% | 10,400 | +5.9% | 0.00% | – |
| Q3 2020 | $110,000 | -22.5% | 9,825 | -6.7% | 0.00% | – |
| Q2 2020 | $142,000 | +992.3% | 10,525 | +530.6% | 0.00% | – |
| Q1 2020 | $13,000 | -35.0% | 1,669 | -21.4% | 0.00% | – |
| Q4 2019 | $20,000 | -13.0% | 2,124 | 0.0% | 0.00% | – |
| Q3 2019 | $23,000 | +35.3% | 2,124 | +44.1% | 0.00% | – |
| Q2 2019 | $17,000 | -10.5% | 1,474 | 0.0% | 0.00% | – |
| Q1 2019 | $19,000 | +216.7% | 1,474 | +44.7% | 0.00% | – |
| Q4 2018 | $6,000 | -45.5% | 1,019 | 0.0% | 0.00% | – |
| Q3 2018 | $11,000 | -26.7% | 1,019 | 0.0% | 0.00% | – |
| Q2 2018 | $15,000 | +7.1% | 1,019 | 0.0% | 0.00% | – |
| Q1 2018 | $14,000 | +16.7% | 1,019 | 0.0% | 0.00% | – |
| Q4 2017 | $12,000 | – | 1,019 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |